Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 5,936 matching trials from the live ClinicalTrials.gov search.
Conditions
Sedentary Behavior, Insulin Sensitivity, Sedentary Lifestyle
Interventions
SIT, ACTIVE, EX
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Conditions
Cytomegalovirus Infections
Interventions
Valganciclovir, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more
Recruiting No phase listed Observational Accepts healthy volunteers

Integrated Cancer Repository for Cancer Research

NCT02012699
Conditions
Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 110 Years
Enrollment
999,999 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
42
States / cities
Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
Conditions
Type 2 Diabetes Mellitus
Interventions
V-Go™
Device
Lead sponsor
Valeritas, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Chula Vista, California • San Francisco, California • Danbury, Connecticut + 20 more
Not yet recruiting Phase 2 Interventional

Early Feeding TL Trial

NCT07919821
Conditions
Total Laryngectomy
Interventions
oral intake
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Elsubrutinib, Placebo for Elsubrutinib, Upadacitinib, Placebo for Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Alamitos, California + 18 more
Conditions
Stomatitis
Interventions
CG53135-05, velafermin
Drug
Lead sponsor
CuraGen Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
9
States / cities
La Jolla, California • Denver, Colorado • Miami, Florida + 6 more
Conditions
Autistic Disorder
Interventions
Fluoxetine (prozac)
Drug
Lead sponsor
Neuropharm
Industry
Eligibility
5 Years to 18 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Sacramento, California • Smyrna, Georgia + 10 more
Conditions
Osteoarthritis
Interventions
AGG-523
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Altoona, Pennsylvania
Conditions
Multiple Myeloma
Interventions
LBH589, Lenalidomide
Drug · Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • New York, New York
Conditions
Obstructive Sleep Apnea
Interventions
Auto-titrating mandibular positioner test
Device
Lead sponsor
Zephyr Sleep Technologies
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bellevue, Washington
Conditions
Healthy
Interventions
Isotretinoin
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited, India
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Quadrangle Drive, Chapel Hill,, North Carolina
Conditions
Periodontitis, Autism, Premature Infants
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Day and older
Enrollment
331 participants
Timeline
2007 – 2013
U.S. locations
4
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
4 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Conditions
Langerhans Cell Histiocytosis
Interventions
GSK2110183
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 2 more
Conditions
Schizophrenic Psychoses
Interventions
n-acetylcysteine, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Eosinophilic Disorder, Food Allergy
Interventions
Entero-tracker, omalizumab, dupliumab
Device · Biological
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Diabetic Retinopathy
Interventions
BI 1467335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Dothan, Alabama • Phoenix, Arizona • Beverly Hills, California + 13 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Larynx, LIP, Oral Cavity, Pharynx
Interventions
Metformin Hydrochloride, Doxycycline, Metformin +Doxycycline
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Osteoporosis
Interventions
Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more
Conditions
Thrombocytopenia Associated With Liver Disease
Interventions
avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
21
States / cities
Lancaster, California • Long Beach, California • Los Angeles, California + 18 more
Conditions
Partial Epilepsies, Partial Onset Seizures
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

NCT01489956
Conditions
Autoimmune Disorders
Interventions
Immucothel Alone (Part A), Immucothel+Montanide (Part A), Immucothel Alone or Immucothel+Montanide (Part B)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York